Pomalidomide-PEG2-butyl iodide is a high-quality E3 Ligase Ligand-Linker Conjugate designed specifically for PROTAC (Proteolysis Targeting Chimera) research and drug development. This compound features pomalidomide, a well-established ligand for the CRBN (cereblon) E3 ubiquitin ligase, linked via a flexible PEG2 spacer to a butyl iodide functional group, making it ideal for coupling with various target protein ligands. As a PROTAC intermediate, Pomalidomide-PEG2-butyl iodide enables researchers to efficiently design and synthesize bifunctional molecules that harness the cell's ubiquitin-proteasome system for selective protein degradation. Its versatile structure supports the rapid development of next-generation therapeutics targeting disease-related proteins, including those implicated in cancer, neurodegeneration, and other pathologies. This product is an essential tool for medicinal and chemical biology researchers pioneering targeted protein degradation strategies.
Structure of 1835705-72-0
* For research and manufacturing use only. Not for human or clinical use.
| Size | Price | Stock | Quantity |
|---|---|---|---|
| -- | $-- | In stock |
Looking for different specifications? Click to request a custom quote!
Capabilities & Facilities
Popular Publications Citing BOC Sciences Products
Background Introduction
Pomalidomide-PEG2-butyl iodide is a specialized E3 ligase ligand-linker conjugate designed for use in the synthesis of PROTACs (Proteolysis Targeting Chimeras). Pomalidomide acts as a cereblon (CRBN) E3 ligase ligand, while the PEG2 (polyethylene glycol spacer) and butyl iodide group offer enhanced solubility and chemical versatility for coupling to various target protein ligands. This makes Pomalidomide-PEG2-butyl iodide an optimal choice for researchers seeking to develop next-generation protein degraders.
Mechanism
The mechanism of action of Pomalidomide-PEG2-butyl iodide is rooted in its role as a E3 ligase ligand within bifunctional PROTAC molecules. The pomalidomide moiety selectively binds to the cereblon (CRBN) E3 ubiquitin ligase complex. The PEG2 linker provides spatial flexibility and improved solubility, while the terminal butyl iodide group acts as a reactive handle for chemical conjugation. Upon incorporation into a PROTAC, this conjugate facilitates the recruitment of the E3 ligase to a target protein, leading to polyubiquitination and subsequent proteasomal degradation of the target protein within cells.
Applications
Pomalidomide-PEG2-butyl iodide is widely used as a chemical scaffold in the construction of custom PROTAC molecules. Its applications include the targeted degradation of disease-associated proteins in cancer biology, neurodegenerative disorders, and drug discovery research. This conjugate enables researchers to efficiently design and synthesize protein degraders with tailored selectivity and potency. It is also valuable for generating tool compounds to investigate protein function, validate therapeutic targets, and accelerate the development of novel protein degradation-based drugs.
Pomalidomide-PEG2-butyl iodide is a versatile E3 Ligase Ligand-Linker Conjugate that plays a critical role in the development of PROTACs, facilitating targeted protein degradation. It offers a strategic combination of a pomalidomide ligand, a PEG2 linker, and a butyl iodide reactive site, providing researchers with a robust tool for selective protein targeting. The following provides a detailed description of this molecule.
Linker: The PEG2 linker in this molecule is characterized by its moderate length and flexibility, allowing for optimal spatial orientation between the ligand and target protein. Its non-cleavable nature ensures stability within the cellular environment, making it suitable for prolonged studies.
Ligand: The ligand component, pomalidomide, is a thalidomide derivative known for its ability to recruit cereblon, an E3 ubiquitin ligase. Its structural characteristics include a glutarimide ring essential for binding, providing specificity and efficacy in protein degradation applications.
Reactive Site: The butyl iodide group serves as the reactive site, enabling efficient coupling with nucleophilic groups on the target protein ligand. Recommended reaction types include nucleophilic substitution, which facilitates the formation of a stable covalent bond.
Recommended Target Protein Ligand: A suitable warhead for this molecule would be a nucleophilic amine-containing ligand, which can effectively react with the butyl iodide site. This combination offers the advantage of forming a stable, irreversible bond, enhancing the efficacy of protein degradation. It is particularly useful in applications requiring precise targeting and sustained degradation of pathogenic proteins.
* Our calculator is based on the following equation:
Concentration (start) x Volume (start) = Concentration (final) x Volume (final)
It is commonly abbreviated as: C1V1 = C2V2
Please contact us with any specific requirements and we will get back to you as soon as possible.